Confluent and reticulate papillomatosis is a rare but clinically distinct dermatosis first described by Gougerot and Carteaud in 1927. It consists of dark brown pigmented papules which coalesce to reticulate and confluent patches. It usually begins shortly after puberty mainly in females and is most often localized to the intermammary and interscapular regions. Histological examination shows hyperkeratosis and papillomatosis, and there may be decreased granular cell layer, focal acanthosis, or hypermelanosis of the basal cell layer. We recently observed a 20-year-old male patient who showed typical clinical and histopathological findings of confluent and reticuIate papillomatosis. Treatment with an aromatic analog of vitamin A acid(Ro 10-9359) resulted in dramatic effectivenese.
Adolescent ; Female ; Humans ; Hyperpigmentation ; Male ; Papilloma* ; Puberty ; Skin Diseases ; Tretinoin* ; Vitamin A* ; Vitamins* ; Young Adult

PURPOSE: The prognosis for breast carcinoma in young women, especially those less than 35 years of age, is perceived as being unfavorable. However, the relationship of age at diagnosis and prognosis still remains controversial. METHODS: We retrospectively studied 37 breast cancer patients, who had been 35 years old or younger at the time of their diagnosis from Jan. 1990 to Dec. 1994 at the Department of Surgery, Chungnam National University Hospital. RESULTS: The factors that influenced survival were pathologic stage, tumor size, and the number of axillary node metastases, but operation method, postoperative radiation therapy, and neoadjuvant chemotherapy did not. CONCLUSION: When we compared the group with age < or =35 to the group with age >35, the former group showed worse disease free survival, but the overall survival was not worse.
Adult ; Breast Neoplasms* ; Breast* ; Chungcheongnam-do ; Diagnosis ; Disease-Free Survival ; Drug Therapy ; Female ; Humans ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies ; Survival Rate

Pseudolipoma of Glisson’s capsule is a rare benign fatty mass that develops in the subcapsular space of the liver, typically at the interface between the diaphragm and the liver. Histologically, it resembles an epiploic appendage. This report describes a case in which a newly formed hepatic pseudolipoma migrated during follow-up. Positional changes in pseudolipomas are exceedingly rare, with only one other case documented in the literature. This case supports the hypothesis that a lipomatous mass originating from an epiploic appendage can migrate between the serosa of the liver and Glisson’s capsule, eventually forming a pseudolipoma. We present this case to provide valuable insights into the limited literature on this rare phenomenon.

Pseudolipoma of Glisson’s capsule is a rare benign fatty mass that develops in the subcapsular space of the liver, typically at the interface between the diaphragm and the liver. Histologically, it resembles an epiploic appendage. This report describes a case in which a newly formed hepatic pseudolipoma migrated during follow-up. Positional changes in pseudolipomas are exceedingly rare, with only one other case documented in the literature. This case supports the hypothesis that a lipomatous mass originating from an epiploic appendage can migrate between the serosa of the liver and Glisson’s capsule, eventually forming a pseudolipoma. We present this case to provide valuable insights into the limited literature on this rare phenomenon.

Pseudolipoma of Glisson’s capsule is a rare benign fatty mass that develops in the subcapsular space of the liver, typically at the interface between the diaphragm and the liver. Histologically, it resembles an epiploic appendage. This report describes a case in which a newly formed hepatic pseudolipoma migrated during follow-up. Positional changes in pseudolipomas are exceedingly rare, with only one other case documented in the literature. This case supports the hypothesis that a lipomatous mass originating from an epiploic appendage can migrate between the serosa of the liver and Glisson’s capsule, eventually forming a pseudolipoma. We present this case to provide valuable insights into the limited literature on this rare phenomenon.

Pseudolipoma of Glisson’s capsule is a rare benign fatty mass that develops in the subcapsular space of the liver, typically at the interface between the diaphragm and the liver. Histologically, it resembles an epiploic appendage. This report describes a case in which a newly formed hepatic pseudolipoma migrated during follow-up. Positional changes in pseudolipomas are exceedingly rare, with only one other case documented in the literature. This case supports the hypothesis that a lipomatous mass originating from an epiploic appendage can migrate between the serosa of the liver and Glisson’s capsule, eventually forming a pseudolipoma. We present this case to provide valuable insights into the limited literature on this rare phenomenon.

No abstract available.
Drug Therapy* ; Etoposide* ; Humans ; Leukemia* ; Mitoxantrone*

Baicalin is flavonoid and major component of PC-SPES. Flavonoids including baicalin have been reported to not only function as anti-oxidant but also cause cytotoxic effect. Baicalin hydrate has been reported to induce cell death, however the mechanism by which baicalin hydrate induces the apoptosis of cancer cells is still unclear. To evaluate the mechanistic insights of apoptosis by baicalin hydrate, we tested the activities of apoptosis signaling pathway in HeLa cells. The viability of HeLa and HeLa s3 cells was markedly decreased by baicalin hydrate in a dose- and time- dependent method. Baicalin hydrate induced the apoptotic death of HeLa cells, which was characterized by the chromatin condensation of the nuclei and phosphorylation of histone H2AX. Baicalin hydrate increased the sub-G1 DNA content of HeLa cell lines. Baicalin hydrate digested Bid protein, increased Bak protein level and also, induced mitochondrial dysfunction disrupted as shown as the mitochondrial membrane potential. It activated caspase-3, thereby resulted in cleavage of poly (ADP) ribose polymerase (PARP).
Apoptosis ; bcl-2 Homologous Antagonist-Killer Protein ; BH3 Interacting Domain Death Agonist Protein ; Caspase 3 ; Cell Death ; Chromatin ; DNA ; Flavonoids ; HeLa Cells ; Histones ; Humans ; Membrane Potential, Mitochondrial ; Phosphorylation ; Ribose ; Signal Transduction*

Polyomavirus infection commonly occurs in childhood and adolescence, remaining in a latent status and reactivated in an immunocompromised status. We report herein an autopsy case of HIV-positive 41-year-old male, who succumbed to disseminated Kaposi sarcoma and cytomegalovirus infection involving the gastrointestinal tract, lung and brain. The involved kidney showed minimal inflammatory infiltrates and tubular injury: the nuclei of tubular epithelial cells were markedly enlarged with central clearing and peripheral chromatin margination or bore basophilic nuclear inclusions. Inclusion-bearing tubular epithelial cells were negative for the viral immunostains including herpes simplex virus, Epstein-Barr virus and adenovirus. Electron microscopy disclosed 42 nm intranuclear viral particles compatible with the BK polyomavirus. The viral particles were icosahedral in paracrystalline array and nonenveloped.
Acquired Immunodeficiency Syndrome* ; Adenoviridae ; Adolescent ; Adult ; Autopsy* ; Basophils ; BK Virus ; Brain ; Chromatin ; Cytomegalovirus Infections ; Epithelial Cells ; Gastrointestinal Tract ; Herpesvirus 4, Human ; HIV ; Humans ; Intranuclear Inclusion Bodies ; Kidney ; Lung ; Male ; Microscopy, Electron* ; Polyomavirus Infections ; Polyomavirus* ; Sarcoma, Kaposi ; Simplexvirus ; Virion

BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by chronic complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody against the terminal complement protein C5, potently reduces chronic intravascular hemolysis. We tested the clinical efficacy and safety of a 24-week treatment with eculizumab in 6 Korean patients with PNH. METHODS: We enrolled 6 patients with PNH who had clinically significant hemolysis. Eculizumab was administered intravenously at 600 mg/week for the first 4 weeks followed by 900 mg at week 5 and 2nd weekly thereafter. RESULTS: Three men and 3 women with a median age of 39.5 years (24-61 years) were enrolled. The median duration of PNH was 11 years (6-25 years). Hemolysis occurred in all patients [median lactate dehydrogenase (LDH) level, 7.95 times the upper limit of the reference range of LDH]. All patients treated with eculizumab had a rapid and sustained reduction in the degree of hemolysis. RBC transfusion requirements for 3 months were decreased from 0-12 units (median requirement, 1.5 units) to 0-6 units (median requirement, 0 units). Improvement in fatigue was noted in 4 patients. Further, 5 patients who had been receiving corticosteroids either reduced the dose or discontinued therapy. No significant adverse events related to eculizumab therapy were observed. CONCLUSION: These results show that eculizumab reduces the degree of intravascular hemolysis, reduces or eliminates the requirement of RBC transfusion, and improves anemia and fatigue in patients with PNH. Eculizumab is an effective and safe option for treating Korean patients with PNH.
Adrenal Cortex Hormones ; Anemia ; Antibodies, Monoclonal, Humanized ; Complement System Proteins ; Fatigue ; Female ; Hemoglobinuria, Paroxysmal ; Hemolysis ; Humans ; L-Lactate Dehydrogenase ; Male ; Reference Values